A new integrated computational method helps predicting adverse drug reaction-which are often lethal-more reliably than with traditional computing methods. This improved ability to foresee the possible adverse effects of drugs may entail saving many lives in the future. The study that is being conducted by researchers from Systems Pharmacology group of GRIB (IMIM-UPF), and the company Chemotargets, within the framework of the European project eTOX, was chosen for the cover of the journal Chemical Research in Toxicology.
Jordi Mestres, coordinator of the Systems Pharmacology group of GRIB states 'With this study we have contributed to complementing the detection of these quite unstable fragments, with information on the mechanism of action of the drug, based on three aspects: similarity to other medicines, prediction of their pharmacological profile, and interference with specific biological pathways. The optimal integration of these four aspects results in a clear improvement of our ability to anticipate adverse effects with higher confidence, which entails an extremely positive impact on society'.
The aim of the annual DCEXS symposium is to show the department's research programmes and promote the education of the young researchers, as well as provide a place where the researchers can discuss their latest results.
The DCEXS director, Arcadi Navarro, will welcome the journey together with Jorge Cuneo, the medical director of Novartis and patron of the 25 th anniversary of the UPF, and Ferran Sanz, director of GRIB. Among the invited speakers are Marta Filizola, principal investigator at the Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai (New York); Joaquin Dopazo, director of the Department of Computational Genomics of the Príncipe Felipe Research Centre (Valencia), and Alfonso Valencia, leader of the Computational and Structural Biology group of the Spanish National Cancer Research Centre (CNIO) and director of the Spanish National Institute for Bioinformatics. The program is completed with a number of leading researchers in biomedicine that will explore advances in the in silico strategies.
The project MedBioinformatics "Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities" aims to develop useful bioinformatics tools and applications, and autonomously usable for analysing the huge amount of data and knowledge generated in healthcare and biomedical research in order to facilitate translational research and precision medicine. European project funded by H2020 for the period 2015-2018 and coordinated by the GRIB.